IMC Chicago’s Summit Therapeutics SMMT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$5.06M Buy
299,400
+120,600
+67% +$1.8M ﹤0.01% 2306
2026
Q2
$2.61M Buy
178,800
+84,800
+90% +$1.5M ﹤0.01% 2867
2026
Q1
$1.78M Buy
94,000
+10,300
+12% +$167K ﹤0.01% 2810
2025
Q4
$1.46M Sell
83,700
-91,600
-52% -$1.72M ﹤0.01% 2796
2025
Q3
$3.62M Sell
175,300
-151,300
-46% -$3.67M ﹤0.01% 1887
2025
Q2
$6.95M Buy
+326,600
New +$7.45M ﹤0.01% 1252

Other funds holding SMMT

IMC Chicago's SMMT Position: Q3 2026 in Review

IMC Chicago opened a new position in Summit Therapeutics (SMMT) in Q3 2026: 55,491 shares worth $938K. The stake represents ﹤0.01% of the portfolio and ranks #4138 among its holdings. This is a return to the name: IMC Chicago previously reported a position in SMMT as recently as Q4 2025.

IMC Chicago first reported a position in SMMT in Q4 2025 and has held it in 2 quarters since. 298 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.

  • IMC Chicago held 55,491 shares of Summit Therapeutics worth $938K as of Q3 2026.
  • Summit Therapeutics was a new IMC Chicago position in Q3 2026.
  • Summit Therapeutics made up ﹤0.01% of IMC Chicago's portfolio in Q3 2026, its #4138 holding.
  • IMC Chicago first reported a position in Summit Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 298 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.

Based on IMC Chicago's 13F filing for Q3 2026, filed 5 Nov 2026.